InnoCan Pharma Corporation (CSE:INNO)
2.440
+0.090 (3.83%)
Sep 17, 2026, 5:16 PM EST
InnoCan Pharma Revenue
InnoCan Pharma had revenue of $5.25M USD in the quarter ending June 30, 2026, a decrease of -25.06%. This brings the company's revenue in the last twelve months to $23.53M, down -18.39% year-over-year. In the year 2025, InnoCan Pharma had annual revenue of $26.61M, down -9.60%.
Revenue (ttm)
$23.53M
Revenue Growth
-18.39%
P/S Ratio
0.33
Revenue / Employee
$4.71M
Employees
5
Market Cap
10.98M CAD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.61M | -2.83M | -9.60% |
| Dec 31, 2024 | 29.44M | 15.78M | 115.55% |
| Dec 31, 2023 | 13.66M | 11.10M | 433.69% |
| Dec 31, 2022 | 2.56M | 2.36M | 1,205.61% |
| Dec 31, 2021 | 196.00K | 188.00K | 2,350.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| George Weston | 65.69B |
| Loblaw Companies | 65.07B |
| Metro | 22.48B |
| Dollarama | 7.88B |
| Big Rock Brewery | 49.00M |
| Green Rise Foods | 32.94M |
| Diamond Estates Wines & Spirits | 28.68M |
| Eshbal Functional Food | 22.44M |
InnoCan Pharma News
- 19 days ago - InnoCan Pharma Registration statement: Q2 2026 - Filings
- 19 days ago - InnoCan Pharma Earnings release: Q2 2026 - Filings
- 19 days ago - InnoCan Pharma Registration statement: Q2 2026 - Filings
- 3 months ago - InnoCan Pharma Registration statement: Q1 2026 - Filings
- 3 months ago - InnoCan Pharma Registration statement: Q1 2026 - Filings
- 3 months ago - InnoCan Pharma Earnings release: Q1 2026 - Filings
- 5 months ago - InnoCan Pharma Earnings release: Q4 2025 - Filings
- 5 months ago - InnoCan Pharma Registration statement: Q4 2025 - Filings